Close

Omeros (OMER) Announces Results from OMS906 Complement Program

August 4, 2016 7:40 AM EDT Send to a Friend
Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login